Burkina Faso increases state ownership in gold projects as new mining law takes effect
Burkina Faso has officially increased its free-carried equity stake in key gold mining projects from 10% to 15%, aligning with the provisions of its new Mining Code adopted in August 2024.
This adjustment affects several high-profile assets, including the Sanbrado, Kiaka, and Toega projects operated by Australia-listed West African Resources.
The company agreed to the new terms after talks with the government and other key players in the mining industry.
In simple terms, this new regulation means Burkina Faso will now earn a bigger slice of the gold profits from mines on its land, without having to spend a dime.
Mining Weekly reports that aside from the change to the State's equity interest, all other key terms of West African Resources' existing mining agreements with the Burkina Faso government remain unchanged.
'Our 2025 cost and production guidance of 190,000 to 210,000 ounces of gold at an all-in sustaining cost of less than $1,350 per ounce remains intact,' said West African Resources Chairperson, Richard Hyde.
He added that construction at the Kiaka project is progressing on schedule and within budget, with the first gold pour expected early in the third quarter of this year.
Burkina Faso's mining sector reforms
Burkina Faso's status as a gold producer has grown significantly over the past two decades, making it one of Africa's leading gold-producing countries.
The nation ranks fourth in gold production after Ghana, South Africa, and Sudan. Gold is Burkina Faso's most valuable export, contributing over 70% of export earnings and serving as a cornerstone of its economy.
Since taking power in 2022, Captain Ibrahim Traoré has made resource sovereignty a core priority, insisting that Burkinabè citizens must benefit more from the country's gold wealth.
Under his leadership, the government adopted a new Mining Code in August 2024, raising the state's free-carried interest in mining projects from 10% to 15% to strengthen national control and revenue.
Captain Ibrahim Traoré's decision to reform Burkina Faso's mining laws was largely driven by a desire to reassert national control over a sector long dominated by foreign interests.
For years, foreign companies from Canada, Australia, and the UK have dominated Burkina Faso's gold sector, contributing capital and expertise but offering limited benefits to local communities.
Most profits have been repatriated, with only small portions retained through taxes and minimal state equity.
Under the revised 2024 Mining Code, all mining firms must now grant the state a 15% free-carried interest giving the government a larger, cost-free stake.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Blue Earth Summit highlights regenerative wool's climate potential
The discussion titled 'Circular by Nature – Rethinking Innovation in Natural Fibres' was held at the London Climate Action Week. It centred on the tangible benefits of wool, supported by evidence-based land management practices, innovative product development, and circular design principles. The panel, moderated by Amy Nguyen, featured participants including Clare Cannon, a Merino woolgrower from 'Woomargama Station' in Australia; Chris Gaffney, CEO of Johnsons of Elgin; Amy Powney, creative director and founder at AKYN; and Elisabeth van Delden, sustainability manager for Europe at Woolmark. The panellists emphasised the need for increased cooperation across the sector and promoted regenerative wool as a beneficial solution for the environment. Central to this conversation was the Woolmark+ roadmap, which outlines a strategy for incorporating wool into sustainable fashion models. This framework focuses on enhancing nature-positive production, establishing wool as a preferred circular fibre, and fostering prosperous rural communities. Australian woolgrower Clare Cannon provided insights into the positive ecological effects of regenerative grazing on her farm, including the resurgence of endangered bird species and native vegetation. 'Our expertise isn't theoretical; it's grounded in day-to-day realities. We have implemented practical strategies for preserving biodiversity, improving soil health, and reducing emissions as we journey towards nature positive. These are not buzzwords for us but part of our innate identity as stewards of the land,' Cannon stated. Gaffney discussed how continuous innovation is essential for maintaining the longevity of brands. 'You don't become a heritage brand without constantly innovating,' he said. van Delden highlighted current global carbon accounting methods prioritise carbon emissions and neglect factors such as water management, biodiversity and soil health. 'Woolmark+ helps bridge the gap between real on-farm outcomes and the growing demand from brands and investors for measurable impact. Whether it's decarbonisation, biodiversity uplift, or material circularity - the roadmap offers a science-led, scalable way to integrate wool into strategies focused on risk reduction, resilience, and long-term value creation,' she said. In November 2024, the Australian Government allocated A$4m ($2.6m) to support Woolmark's new Australian Wool Industry Insetting Programme, which is designed to lower emissions within the textile supply chain. "Blue Earth Summit highlights regenerative wool's climate potential" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Insider
an hour ago
- Business Insider
Burkina Faso mine delivers first gold pour as Australian firm hits milestone
West African Resources has achieved a major milestone at its Kiaka gold project in Burkina Faso, successfully producing its first gold bar measuring 5.7 kilograms, or approximately 183.3 ounces—during an on-site smelting process. West African Resources achieved its first gold bar production at its Kiaka project in Burkina Faso. The project was completed ahead of schedule and under budget, indicating strong operational efficiency. Burkina Faso has implemented mining reforms to enhance state control and economic benefits. The Australian-listed company confirmed the development came ahead of schedule and under budget, marking a strong start to what is projected to become one of the region's most significant gold operations. According to Miningmx, West African Resources Executive Chairman Richard Hyde described the first gold pour from the Kiaka mine as ' a major milestone ' in the company's goal to produce over 500,000 ounces of gold annually by 2030. ' First gold comes just three and a half years after the acquisition of Kiaka, which is a remarkable achievement,' Hyde said, expressing gratitude to the construction team, financial partners Sprott and Coris Bank, as well as contractors and stakeholders for their contributions. In November 2021, West African acquired a 90% stake in the Kiaka Gold Project in Burkina Faso from B2Gold Corp and its partner, GAMS-Mining F&I. The remaining 10% is held by the Government of Burkina Faso. The company completed construction at the site during the second quarter of 2025, keeping pace with its aggressive project timeline. The inaugural gold pour not only signals the operational readiness of the Kiaka mine but also reflects investor confidence in West African Resources' ability to deliver in one of Africa's most promising, yet geopolitically complex, mining jurisdictions. Burkina Faso's move to secure gold and raise revenue Burkina Faso is reshaping its gold sector through sweeping reforms aimed at increasing state control, boosting revenues, and ensuring that more benefits stay within the country. Gold is central to the nation's economy, accounting for around 80% of export earnings and nearly 14% of GDP. However, much of this value has historically escaped government capture due to foreign ownership, weak regulation, and illicit exports. In July 2024, the government revised its mining code to raise the state's free equity in new projects from 10% to 15%, with an option to acquire an additional 15%. It also mandated greater Burkinabè ownership and shortened permit durations to strengthen oversight. Companies are now required to contribute to national gold and mining development funds, as well as process part of their output domestically to retain more value in-country. The state has also taken over several major mines through SOPAMIB, a new state-owned company, consolidating national control of key gold assets. Additionally, a national gold refinery is being built in Ouagadougou to reduce reliance on foreign processing and improve export transparency. Small-scale export permits have been temporarily suspended to curb illegal trade.
Associated Press
an hour ago
- Associated Press
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP® platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'This latest patent acceptance from Australia represents another important achievement in our efforts to secure international IP protection for our DRP® technology. As we continue advancing stenoparib through Phase 2 trials toward U.S. regulatory approval, we are also building a robust intellectual property position in key global markets.' Allarity previously secured a European patent for the Stenoparib DRP® and holds 18 granted patents for drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP® remain pending in the U.S., Canada, Japan, China, and India. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the Australian patent for the Stenoparib DRP®; the anticipated contribution of this patent to the Company's global intellectual property strategy; and the Company's ability to advance and commercialize stenoparib in Australia and other key markets. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the potential for opposition to the patent grant; changes in regulatory timelines or requirements; failure to obtain regulatory approval for stenoparib or its companion diagnostic; and risks inherent in developing and commercializing biopharmaceutical products. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected] Attachment
